CN102078600B - 抗癌复方灵芝组合物、其用途和包含其的药物组合物 - Google Patents
抗癌复方灵芝组合物、其用途和包含其的药物组合物 Download PDFInfo
- Publication number
- CN102078600B CN102078600B CN201010606323.7A CN201010606323A CN102078600B CN 102078600 B CN102078600 B CN 102078600B CN 201010606323 A CN201010606323 A CN 201010606323A CN 102078600 B CN102078600 B CN 102078600B
- Authority
- CN
- China
- Prior art keywords
- parts
- ganoderma
- carcinoma
- compound ganoderma
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 56
- 241000222336 Ganoderma Species 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 40
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 28
- 239000004365 Protease Substances 0.000 claims abstract description 27
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 108091005804 Peptidases Proteins 0.000 claims abstract description 16
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 16
- 201000011510 cancer Diseases 0.000 claims abstract description 15
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 14
- DSRNKUZOWRFQFO-UHFFFAOYSA-N cephalotaxine Natural products COC1=CC23CCCN2CCc4cc5OCOc5cc4C3=C1O DSRNKUZOWRFQFO-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 14
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 14
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 11
- 239000005017 polysaccharide Substances 0.000 claims abstract description 11
- 150000004676 glycans Chemical class 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 16
- 244000050510 Cunninghamia lanceolata Species 0.000 claims description 15
- 235000019419 proteases Nutrition 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 241000186660 Lactobacillus Species 0.000 claims description 11
- 108090000526 Papain Proteins 0.000 claims description 11
- 229940039696 lactobacillus Drugs 0.000 claims description 11
- 229940055729 papain Drugs 0.000 claims description 11
- 235000019834 papain Nutrition 0.000 claims description 11
- 230000003203 everyday effect Effects 0.000 claims description 10
- 238000000855 fermentation Methods 0.000 claims description 10
- 230000004151 fermentation Effects 0.000 claims description 10
- 150000001447 alkali salts Chemical class 0.000 claims description 8
- 238000010790 dilution Methods 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 7
- 108010001062 polysaccharide-K Proteins 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 238000005342 ion exchange Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000008275 breast carcinoma Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 4
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 4
- 201000010175 gallbladder cancer Diseases 0.000 claims description 4
- 201000007487 gallbladder carcinoma Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 239000002398 materia medica Substances 0.000 claims description 4
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 210000000664 rectum Anatomy 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 27
- 238000002512 chemotherapy Methods 0.000 abstract description 23
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000036737 immune function Effects 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 2
- 238000010809 targeting technique Methods 0.000 abstract description 2
- 210000001835 viscera Anatomy 0.000 abstract description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 3
- 206010004542 Bezoar Diseases 0.000 abstract 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 241000222355 Trametes versicolor Species 0.000 abstract 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- YMNCVRSYJBNGLD-KURKYZTESA-N cephalotaxine Chemical compound C([C@@]12C=C([C@H]([C@H]2C2=C3)O)OC)CCN1CCC2=CC1=C3OCO1 YMNCVRSYJBNGLD-KURKYZTESA-N 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 description 30
- 108090000790 Enzymes Proteins 0.000 description 30
- 229940088598 enzyme Drugs 0.000 description 30
- 239000004743 Polypropylene Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 18
- 208000002193 Pain Diseases 0.000 description 17
- 239000002253 acid Substances 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- -1 selenium polysaccharide Chemical class 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 240000008397 Ganoderma lucidum Species 0.000 description 6
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 6
- 244000153234 Hibiscus abelmoschus Species 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 239000003513 alkali Substances 0.000 description 6
- 229910052711 selenium Inorganic materials 0.000 description 6
- 239000011669 selenium Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000207961 Sesamum Species 0.000 description 5
- 235000003434 Sesamum indicum Nutrition 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 201000004384 Alopecia Diseases 0.000 description 4
- 231100000360 alopecia Toxicity 0.000 description 4
- 230000003816 axenic effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 201000002364 leukopenia Diseases 0.000 description 4
- 231100001022 leukopenia Toxicity 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 101800000263 Acidic protein Proteins 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920002498 Beta-glucan Polymers 0.000 description 3
- 102000005575 Cellulases Human genes 0.000 description 3
- 108010084185 Cellulases Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 238000005341 cation exchange Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 2
- 241001116468 Cunninghamia Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000903946 Clematidis Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001149649 Taxus wallichiana var. chinensis Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Abstract
Description
实施例 | 需培养的灵芝 | 所用中草药 |
实施例4 | 赤芝 | 田七、赤芍、土茯苓之一或其混合物 |
实施例5 | 黑芝 | 猫爪草 |
实施例6 | 黄芝 | 葶苈子、桔梗之一或其混合物 |
实施例7 | 红芝 | 川乌、威灵仙之一或其混合物 |
实施例8 | 云芝 | 长春花 |
实施例9 | 紫芝 | 花旗参根茎叶 |
实施例10 | 白芝 | 藤梨根 |
组别 | TNM |
Ⅱ期(例) | Ⅲ期(例) | Ⅳ期(例) | 合计(例) | |
治疗组 | 140 | 102 | 90 | 332 |
对照组 | 10 | 60 | 30 | 100 |
组别 | 轻度疼痛(例) | 中度疼痛(例) | 重度疼痛(例) | 合计(例) |
治疗组 | 16 | 79 | 84 | 179 |
对照组 | 12 | 25 | 28 | 65 |
组别 | 例数 | CR | PR | SD | PD | 稳定以上百分率(%) |
治疗组 | 332 | 0 | 241 | 0 | 10 | 75% |
对照组 | 100 | 35% |
过敏反应 | 发生周期数 | % |
脸色潮红 | 87 | 41.0 |
皮疹 | 9 | 4.2 |
荨麻疹 | 8 | 3.8 |
胸闷 | 2 | 0.9 |
寒战 | 1 | 0.5 |
低血压 | 1 | 0.5 |
支气管痉挛 | 0 | … |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010606323.7A CN102078600B (zh) | 2010-12-24 | 2010-12-24 | 抗癌复方灵芝组合物、其用途和包含其的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010606323.7A CN102078600B (zh) | 2010-12-24 | 2010-12-24 | 抗癌复方灵芝组合物、其用途和包含其的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102078600A CN102078600A (zh) | 2011-06-01 |
CN102078600B true CN102078600B (zh) | 2014-03-26 |
Family
ID=44084926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010606323.7A Expired - Fee Related CN102078600B (zh) | 2010-12-24 | 2010-12-24 | 抗癌复方灵芝组合物、其用途和包含其的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102078600B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105233255A (zh) * | 2015-10-16 | 2016-01-13 | 郭艳 | 一种用于病理性脱发的中西药复方护理剂及其制备方法 |
CN109010354A (zh) * | 2018-09-15 | 2018-12-18 | 黄泳华 | 含有伊马替尼与植物多糖的组合物 |
CN114306580A (zh) * | 2021-04-22 | 2022-04-12 | 庞作仁 | 复方紫杉醇抗白血病胶囊药片制作方法及工艺 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101181052A (zh) * | 2007-12-14 | 2008-05-21 | 广东省微生物研究所 | 一种云芝多糖的制备方法 |
CN101492455A (zh) * | 2009-03-03 | 2009-07-29 | 南开大学 | 光学纯左旋三尖杉碱和分离提纯方法 |
CN101805414A (zh) * | 2010-04-06 | 2010-08-18 | 无限极(中国)有限公司 | 一种高得率的灵芝多糖的制备方法 |
CN101869586A (zh) * | 2009-04-22 | 2010-10-27 | 张鹏 | 一种高纯度紫杉醇及其衍生物的提取方法 |
CN101880700A (zh) * | 2010-07-20 | 2010-11-10 | 山东省农业科学院土壤肥料研究所 | 一种提高灵芝多糖产量的液体发酵方法 |
-
2010
- 2010-12-24 CN CN201010606323.7A patent/CN102078600B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101181052A (zh) * | 2007-12-14 | 2008-05-21 | 广东省微生物研究所 | 一种云芝多糖的制备方法 |
CN101492455A (zh) * | 2009-03-03 | 2009-07-29 | 南开大学 | 光学纯左旋三尖杉碱和分离提纯方法 |
CN101869586A (zh) * | 2009-04-22 | 2010-10-27 | 张鹏 | 一种高纯度紫杉醇及其衍生物的提取方法 |
CN101805414A (zh) * | 2010-04-06 | 2010-08-18 | 无限极(中国)有限公司 | 一种高得率的灵芝多糖的制备方法 |
CN101880700A (zh) * | 2010-07-20 | 2010-11-10 | 山东省农业科学院土壤肥料研究所 | 一种提高灵芝多糖产量的液体发酵方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102078600A (zh) | 2011-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102428832B (zh) | 一种具有降血糖功效的真菌药性菌质及其制备方法 | |
CN102178100B (zh) | 一种低色氨酸杂交鸡饲料及其制备方法 | |
CN102600212B (zh) | 一种增强免疫力、辅助治疗肿瘤的医药保健品 | |
CN101181351B (zh) | 一种抗疲劳、增强免疫的中药组合物及其制备方法 | |
CN101711848B (zh) | 一种辅助治疗肿瘤的中药组合物 | |
CN102078600B (zh) | 抗癌复方灵芝组合物、其用途和包含其的药物组合物 | |
CN108066384A (zh) | 一种具有增强免疫力功能的中药制剂及其制备方法 | |
CN103705578B (zh) | 具有降血脂与抑制血糖升高作用的中药制剂及其制备方法 | |
CN101011457A (zh) | 一种具有增强免疫作用的中药组合物 | |
CN100406026C (zh) | 一种治疗慢性胃炎、胃癌的药物及其制备方法 | |
CN102423384B (zh) | 一种治疗肺癌的中药制剂及其制备方法 | |
CN111743066A (zh) | 一种药食同源中药组合物及其应用 | |
CN111671822A (zh) | 一种可有效治疗僵猪的复方组分 | |
CN102631506B (zh) | 提高免疫力、抗疲劳的中药组合物 | |
CN103520684A (zh) | 一种降血糖的中药复合物 | |
CN102631487B (zh) | 提高免疫力、抗疲劳的中药组合物 | |
CN101019920A (zh) | 一种具有增强免疫作用的中药组合物软胶囊 | |
CN102631486B (zh) | 一种保健组合物 | |
CN106421154A (zh) | 一种具有修复细胞、抗衰老、抗癌功能的沉香中药组合物、中药制剂及其制备方法 | |
CN104096065A (zh) | 一种治疗非小细胞肺癌的中药组合物 | |
CN104758749A (zh) | 一种治疗肝癌的中药组合物 | |
CN104840746B (zh) | 一种具有抗肺癌活性的中药组合物及其制备方法和应用 | |
CN101019911B (zh) | 一种具有增强抗疲劳和调节免疫作用的中药组合物 | |
CN102716382A (zh) | 一种治疗肺癌的中药组合物及其制备方法 | |
CN102631393B (zh) | 一种保健组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151216 Address after: 4102, building 41, building 510627, building B2, 28-5, Fuli square, Fuli Road, Guangzhou, Guangdong Patentee after: Guangzhou lsrd Biotechnology Co., Ltd. Address before: 510623 Guangdong city of Guangzhou province Tianhe District Ping Yun Road No. 177 building 3307 room D Residence Internazionale Marseille Patentee before: Qu Shiheng |
|
TR01 | Transfer of patent right |
Effective date of registration: 20171010 Address after: 510630 Room 203, West 1506, Zhongshan Avenue, Guangzhou, Guangdong, Tianhe District Patentee after: Qu Shiheng Address before: 4102, building 41, building 510627, building B2, 28-5, Fuli square, Fuli Road, Guangzhou, Guangdong Patentee before: Guangzhou lsrd Biotechnology Co., Ltd. |
|
TR01 | Transfer of patent right | ||
DD01 | Delivery of document by public notice |
Addressee: Qu Shiheng Document name: Notification of Termination of Patent Right |
|
DD01 | Delivery of document by public notice | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140326 Termination date: 20171224 |
|
CF01 | Termination of patent right due to non-payment of annual fee |